AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27755543
Drug: Uncontrolled abnormal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncontrolled abnormal glucose metabolism (AGM) among pre-diagnosed diabetic cases
Trial: 25447748
Drug: Thermal cure
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal cure (spa treatment including underwater shower, massage-jet showers, hydromassage, pool rehabilitation, and peloid therapy)
Trial: 25447748
Drug: Non-thermal rehabilitation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thermal rehabilitation (analgesic physiotherapy, muscle strengthening, and group physical rehabilitation)
Trial: 20408861
Drug: Oral NTHi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NTHi treatment
Trial: 18202420
Drug: Urokinase rinses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase rinses (5 mL of 5,000 U/mL) three times weekly
Trial: 18202420
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) three times weekly
Trial: 11056121
Drug: Stop protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop protocol (GnRHa administration stopped with the onset of menses, high doses of gonadotrophins)
Trial: 11056121
Drug: Non-stop protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-stop protocol (long GnRHa suppression with high doses of gonadotrophins)
Trial: 3987071
Drug: Naloxone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (15 mg infusion)
Trial: 3987071
Drug: Naloxone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (30 mg infusion)
Trial: 2906946
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo exposure to aspirin and placebo capsules
Trial: 2764865
Drug: Generalization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generalization of treatment effects
Trial: 19229804
Drug: Mechanical compression
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical compression therapy followed by a compression bandage (302 patients, group 1)
Trial: 11753130
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management (phytotherapy, alpha‐blockers, 5 alpha‐reductase inhibitors)
Trial: 10091954
Drug: Acamprosate 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 2 g daily for 7 days
Trial: 2127674
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nicergoline
Trial: 2127674
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg nicergoline
Trial: 2086492
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg co-dergocrine mesylate (CDM)
Trial: 37863
Drug: Flunitrazepam 1
RxNorm normalized name: flunitrazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1 mg i.v.
Trial: 37863
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg i.v.
Trial: 30290018
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.33% gel once a day for 4 days
Trial: 14602740
Drug: Troglitazone (TGZ)
DrugBank: Troglitazone (DB00197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Troglitazone (TGZ) 150 mg/d
Trial: 14602740
Drug: Troglitazone (TGZ)
DrugBank: Troglitazone (DB00197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Troglitazone (TGZ) 300 mg/d
Trial: 14602740
Drug: Troglitazone (TGZ)
DrugBank: Troglitazone (DB00197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Troglitazone (TGZ) 600 mg/d
Trial: 1860284
Drug: Metronidazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (3 times daily for 7 days)
Trial: 1860284
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 times daily for 7 days)
Trial: 6802408
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg single oral dose)
Trial: 29394491
Drug: l-citrulline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-citrulline (6 g/day)
Trial: 24969056
Drug: Rifaximin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic VSL#3 (450 × 10(9) FU per day)
Trial: 12856483
Drug: Increased digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased digoxin synthesis, decreased membrane Na(+)‐K+ ATPase activity, increased tryptophan catabolites (serotonin, quinolinic acid, and nicotine), decreased tyrosine catabolites (dopamine, noradrenaline, and morphine) in creative individuals; correlated with right hemispheric dominance.
Trial: 12856483
Drug: Decreased digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decreased digoxin synthesis, increased membrane Na(+)‐K+ ATPase activity, decreased tryptophan catabolites (serotonin, quinolinic acid, and nicotine), increased tyrosine catabolites (dopamine, noradrenaline, and morphine) in non-creative individuals; correlated with left hemispheric dominance.
Trial: 8988452
Drug: Trazodone 100
RxNorm normalized name: traZODone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 100 mg/day + Pindolol 7.5 mg/day
Trial: 9315986
Drug: Trazodone 100
RxNorm normalized name: traZODone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 100 mg/day + Fluoxetine 20 mg/day
Trial: 8988452
Drug: Trazodone 100
RxNorm normalized name: traZODone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 100 mg/day + Placebo
Trial: 6439565
Drug: Intranasal disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal disodium chromoglycate
Trial: 29156378
Drug: Robotic-assisted gait
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-assisted gait training therapy using Lokomat®Pediatric, 20 sessions
Trial: 18561722
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day purified omega-3 fatty acids
Trial: 11803070
Drug: 0.5ml (15.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml (15.5 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Trial: 11803070
Drug: 0.25ml (7.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25ml (7.75 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Trial: 10357750
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vitamin E
Trial: 10357750
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vitamin E
Trial: 3127028
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (Premarin, 1.25 mg/day)
Trial: 30610781
Drug: Sequential paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential paclitaxel followed by gemcitabine (4 cycles each)
Trial: 28515196
Drug: Therapist-guided internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT) for 12 weeks
Trial: 28515196
Drug: Therapist-guided internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT)
Trial: 29574635
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mix 25 (LM25)
Trial: 22763161
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin glargine (GL)
Trial: 19717480
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of P(ET,CO(2)) >or=36 mmHg with Wells score <4
Trial: 12204666
Drug: Total radiation
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total radiation dose of 44.7 Gy with a standard deviation of 4.6 Gy
Trial: 11379854
Drug: 1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% amino acid‐based PD solution buffered with bicarbonate (Amino/Bic)
Trial: 11379854
Drug: 1.5% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glucose anhydrous‐containing bicarbonate‐buffered solution (Glu/Bic)
Trial: 11379854
Drug: 1.5% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glucose anhydrous‐based dialysis solution with lactate (Glu/Lac)
Trial: 6489417
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 2.5 g
Trial: 6489417
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 10 g
Trial: 6489417
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 25 g
Trial: 2872336
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 50 g
Trial: 6489417
Drug: Water 300
RxNorm normalized name: clindamycin phosphate/dextrose 5 % in water 300 mg/50 mL INTRAVEN IV SOLUTION, PIGGYBACK, BOTTLE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 300 ml only
Trial: 29552921
Drug: Manual restraint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual restraint (intermittent holding restraint during therapy)
Trial: 22244160
Drug: TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE plus intravenous bevacizumab (10 mg/kg IV every 14 days)
Trial: 12243438
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.25 x 10(6) KIU aprotinin (4 doses)
Trial: 9951268
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg of midazolam (mdz) using a nasal route
Trial: 9951268
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg of diazepam (dz) per os 45' before induction
Trial: 2340945
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg furosemide
Trial: 2661389
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide
Trial: 2015169
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg flosequinan
Trial: 2015169
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg flosequinan
Trial: 6948488
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of a mixture of corticosteroid and local anaesthetic, given once a week for three weeks.
Trial: 6948488
Drug: Occlusal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal treatment including splints, grinding on natural teeth, and occlusal correction of complete dentures.
Trial: 25381096
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with preventive swallowing rehabilitation
Trial: 16000605
Drug: Cisplatin-based adjuvant
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based adjuvant chemotherapy
Trial: 19597387
Drug: Individualized adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized adjuvant chemotherapy (discussed conceptually)
Trial: 9579121
Drug: Full angioscopic
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full angioscopic preparation
Trial: 9054083
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation
Trial: 7647691
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4.4 g n-3 fatty acids/day)
Trial: 7647691
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil supplements
Trial: 791332
Drug: Labetalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (400 mg daily)
Trial: 31301920
Drug: Zoster vaccine
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoster vaccine live (ZVL)
Trial: 31441836
Drug: TXA +
RxNorm normalized name: Tranexamic acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA + Dexa (10 mg Dexa just after anesthesia and repeated at 24 hours post-surgery)
Trial: 19338427
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg (third injection)
Trial: 15515413
Drug: Local injections
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injections of tropisetron
Trial: 15515413
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of local anaesthetics combined with depot corticosteroids
Trial: 15515413
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of prilocaine
Trial: 3624684
Drug: Aerosolized atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized atropine (1.5 mg)
Trial: 3624684
Drug: Aerosolized lidocaine
RxNorm normalized name: Lidocaine Topical Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized lidocaine (80 to 160 mg)
Trial: 3624684
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (50 mg three times daily for 10 doses)
Trial: 27849355
Drug: Acute cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute cocoa flavanol (903 mg)
Trial: 20394488
Drug: High-quality skin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality skin cream
Trial: 20394488
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream vehicle
Trial: 20394488
Drug: Cold cream
RxNorm normalized name: cold cream
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold cream emulsion
Trial: 18028577
Drug: Opioid-free continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free continuous psoas compartment block with 0.75% ropivacaine (0.4 mL kg(‐1) loading dose followed by 10 mL h(‐1) of 0.2% ropivacaine for 48 hours)
Trial: 18028577
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.1% morphine and 0.12% ketorolac at 2 mL h(‐1) for 48 hours
Trial: 16210049
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (desloratadine 5 mg + montelukast 10 mg)
Trial: 12371974
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment after biopsy
Trial: 9925057
Drug: RIF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF with aluminum‐magnesium antacid
Trial: 1958387
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen (TAM) treatment
Trial: 7579503
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic adjuvant therapy (Control)
Trial: 27072796
Drug: Psychotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic treatment recommendation
Trial: 27072796
Drug: Psychotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic treatment recommendation in psychiatric university hospital
Trial: 27072796
Drug: Psychotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic treatment recommendation for patients with F2 diagnosis
Trial: 17158523
Drug: Combined antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antithrombotic therapy (antiplatelet plus moderate-level anticoagulant)
Trial: 8958162
Drug: L-Arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (1 g, two daily dosages)
Trial: 8958162
Drug: L-Arginine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (after crossover)
Trial: 20138778
Drug: Daily respiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily respiratory physiotherapy interventions until discharge
Trial: 15123946
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection for pain relief
Trial: 26630719
Drug: Ketoprofen 12.5
RxNorm normalized name: ketoprofen 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 12.5 mg
Trial: 14980334
Drug: Droperidol 2.5
RxNorm normalized name: droperidol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 2.5 mg i.v.
Trial: 29466249
Drug: TPP-related compounds
RxNorm normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPP-related compounds (specifically bis-TPP, 2-butene-1,4-bis-TPP)
Trial: 29466249
Drug: TPP-related compounds
RxNorm normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPP-related compounds (general)
Trial: 28803715
Drug: 20μg Hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20μg Hepatitis E Virus (HEV) p179 vaccine
Trial: 28803715
Drug: 30μg HEV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30μg HEV vaccine p239 Hecolin (control)
Trial: 28803715
Drug: 40μg Hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40μg Hepatitis E Virus (HEV) p179 vaccine
Trial: 25680558
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of trabectedin treatment after six cycles (27 patients)
Trial: 25680558
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of trabectedin treatment after six cycles (26 patients)
Trial: 25680558
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of trabectedin treatment (27 patients)
Trial: 25680558
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of trabectedin treatment (26 patients)
Trial: 23053269
Drug: Bosutinib 200
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200 mg (single oral dose)
Trial: 18841294
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of Bivalirudin
Trial: 12500072
Drug: Blinded rater's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded rater's guess of treatment assignment
Trial: 10623703
Drug: Docetaxel at
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel at a dose of 100 mg/m(2) intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days
Trial: 9181181
Drug: 65 mg
RxNorm normalized name: opium 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg NET-90
Trial: 9181181
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg NET-90
Trial: 8251354
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cetirizine (10 mg at night) and ranitidine (150 mg twice daily)
Trial: 8251354
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terfenadine (120 mg twice daily) and ranitidine (150 mg twice daily)
Trial: 8251354
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg at night)
Trial: 8251354
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg twice daily)